Background: Current US cervical cancer screening guidelines do not differentiate
recommendations based on a woman's human papillomavirus (HPV) vaccination status …

ContextRecently published results suggest that effective vaccines against cervical cancer—
associated human papillomavirus (HPV) may become available within the next decade …

Background The availability of human papillomavirus (HPV) DNA testing and vaccination
against HPV types 16 and 18 (HPV-16, 18) motivates questions about the cost-effectiveness …

Background: A school-based program with quadrivalent human papillomavirus (HPV)
vaccination was implemented in Alberta in 2008. We assessed the impact of this program on …

Human Papillomavirus (HPV) vaccines will likely have an impact as a preventive strategy for
cervical cancer. Screening for precancerous lesions cannot be discontinued because …

Background Vaccination against the oncogenic human papillomavirus (HPV) types 16 and
18 will reduce the prevalence of these types, thereby also reducing cervical cancer risk in …

Women vaccinated against HPV16/18 are approaching the age for cervical screening;
however, an updated screening algorithm has not been agreed. We use a microsimulation …

Several randomized trials have demonstrated that HPV-based cervical cancer screening is
more effective than cytology-based screening. A pooled analysis of long-term follow-up data …

In Italy, the cohorts of women who were offered Human papillomavirus (HPV) vaccination in
2007/08 will reach the age (25 years) for cervical cancer (CC) screening from 2017. The …

The performance of cervical cancer screening will decline as a function of lower disease
prevalence—a consequence of successful human papillomavirus (HPV) vaccination …